Some Muss and Fuss over at Sequenom

By: TraderMark Wednesday, January 14, 2009 7:42 AM

Symbols: SQNM

Email Article
Bookmark:
Font Size
Print Article

Earlier in the day, however, analysts appeared to doubt that idea.

Oppenheimer analyst Kevin DeGeeter said the company is reporting minimal sales -- it reported negative $700,000 in revenue during the third quarter -- and has less than six months of cash left. That made other offers unlikely in his view.

DeGeeter said Sequenom's offer presented a "great deal" for Exact Sciences, but he said Sequenom does not need to complete the deal and will probably not chase Exact Sciences.

In announcing its offer Friday afternoon, Sequenom said cancer screening is an important field for the company. It believes Exact Sciences' cancer tests fit well with Sequenom's own MassArray genetic research systems and other DNA tests.

In a client note, Lazard Capital Markets analyst Sean Lavin said the deal would help Sequenom fulfill its goal of developing noninvasive cancer diagnostic tests. He wrote that Exact Sciences is one of the leading colon cancer diagnostic companies, and holds valuable patents. It also has relationships with key doctors, which could help sell its products, he said.

Lavin, who rates Sequenom at "Buy," believes that Sequenom would gain additional patent protection on its own products if it buys Exact Sciences' intellectual property. But he said the patents on SEQureDx should hold up even if no deal is made. "Contrary to some market chatter, Exact Sciences does not seem to have any IP that would prevent Sequenom from launching its Down test even if this acquisition does not go through," he wrote.

Long Sequenom in fund and personal account

Related Stories